Information:
Error:
ID
28438
Description
Study part: Neovascular AMD History Screening . A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.
Keywords
Versions (1)
- 1/13/18 1/13/18 -
Copyright Holder
Roche
Uploaded on
January 13, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Neovascular AMD History Screening rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g
Neovascular AMD History Screening
- StudyEvent: ODM
Similar models
Neovascular AMD History Screening
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
NEOVASCULAR AMD HISTORY (SCREENING)
C0242383 (UMLS CUI-1)
C0262926 (UMLS CUI-2)
C0262926 (UMLS CUI-2)
Age related macular degeneration Right Eye
Item
Is Neovascular AMD present in the Right Eye?
boolean
C0242383 (UMLS CUI [1,1])
C0229089 (UMLS CUI [1,2])
C0229089 (UMLS CUI [1,2])
date of diagnosis
Item
If Yes, date when Neovascular AMD was first diagnosed in the Right Eye:
boolean
C2316983 (UMLS CUI [1])
Age related macular degeneration Left eye
Item
Is Neovascular AMD present in the Left Eye?
boolean
C0242383 (UMLS CUI [1,1])
C0229090 (UMLS CUI [1,2])
C0229090 (UMLS CUI [1,2])
date of diagnosis
Item
If Yes, date when Neovascular AMD was first diagnosed in the Left Eye:
date
C2316983 (UMLS CUI [1])